The Grand Opening Of Biocodex Vietnam

Celebrating the Grand Opening of Biocodex Vietnam: From Its Origins To Our Future

The inauguration ceremony of Biocodex Vietnam Co., Ltd. took place on April 4, 2025, at Empress Tower (138-142 Hai Ba Trung, Da Kao, District 1, Ho Chi Minh City). The event was attended by representatives of Biocodex Group leadership, medical experts, strategic partners, honored guests, and press media. Their participation underscored the collaborative spirit that drives our success and our commitment to innovation and excellence in healthcare.

This emotional inauguration brought together Olivier Brochet, French Ambassador to Vietnam, Dr. Duong Huy Luong, Deputy Director of Medical Examination and Treatment Management, Biocodex’s long-standing partners CMS (China) and Kunhil (South Korea), and many Biocodexians who had been dedicated to this project for over two years — their presence was a true sign of trust in Biocodex and recognition of its growing role in healthcare across Asia-Pacific.

"Opening up Vietnam has been a long reflection. About two years ago, we decided to go to Vietnam and a long work to prepare that. But we decided to come here both for the legacy. We have already the products and a large portfolio over 20 years that was distributed by partners, and we thought we could do better. We could do it better, and we decided to invest a high amount of resources in order to do better in a very promising market, a very interesting market, number 15, for the probiotics market and promising for the years to come. That's what led us to Vietnam", said Nicolas Coudurier (CEO, Biocodex Group) — “Opening up Vietnam has been a long reflection. About two years ago, we decided to go to Vietnam and a long work to prepare that. But we decided to come here both for the legacy. We have already the products and a large portfolio over 20 years that was distributed by partners, and we thought we could do better. We could do it better, and we decided to invest a high amount of resources in order to do better in a very promising market, a very interesting market, number 15, for the probiotics market and promising for the years to come. That’s what led us to Vietnam”, said Nicolas Coudurier (CEO, Biocodex Group)

In 1923, in what was then Indochina, Henri Boulard discovered Saccharomyces boulardii CNCM I-745®, the probiotic now recognized worldwide

A century later, we returned to our origins to open a new chapter in our journey

This was an opportunity for Biocodex to officially introduce its long-term strategy in Vietnam, while affirming the company's mission to provide high-quality pharmaceutical products, meeting the increasing healthcare needs in the Vietnamese market — This was an opportunity for Biocodex to officially introduce its long-term strategy in Vietnam, while affirming the company’s mission to provide high-quality pharmaceutical products, meeting the increasing healthcare needs in the Vietnamese market

Located in Ho Chi Minh City, Biocodex Vietnam became not only our first affiliate in Asia, but also the regional headquarters for the Asia-Pacific zone. This strategic milestone reflected our long-term commitment to this key region, with a focus on advancing microbiota care and women’s intimate health.

The event was attended by representatives of Biocodex Group leadership, medical experts, strategic partners, honored guests, and press media

Biocodex Vietnam represented much more than geographic expansion: it was a key step in our mission to deliver innovative, meaningful healthcare solutions to people who need them, all around the world.

The event featured inspiring speeches, a tour of our state-of-the-art facilities, and engaging discussions about our future initiatives. It was a day of celebration, reflection, and anticipation for the exciting journey ahead.

Biocodex is a family-owned multinational pharmaceutical company founded in France in 1953. The initial focus of the company was gastroenterology, featuring a unique probiotic: Saccharomyces boulardii CNCM I-745®, the first probiotic drug to have a positive effect on intestinal microbiota. Today, Biocodex has transformed itself, expanding its development around three pillars, with a strong focus on three main areas: Microbiota, Women’s Health, and Orphan Diseases Solutions. They are represented by 17 different subsidiaries across the globe and over 1,800 employees. Asia is a key region for the Group, Vietnam is a fast-growing country, we discovered our molecule in Vietnam, Biocodex Vietnam is the first affiliate of Biocodex Group in Asia.